Anti-neuroinflammatory effects of psychopharmaceuticals: Further than monoamine modulators

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 553-554

  Hashioka, Sadayuki ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID; CELECOXIB; OMEGA 3 FATTY ACID;

ANTIINFLAMMATORY ACTIVITY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; EDITORIAL; ENCEPHALITIS; GLIA CELL; HUMAN; MOOD DISORDER; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PSYCHOSIS; SCHIZOPHRENIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; FATTY ACIDS, OMEGA-3; HUMANS; MONOAMINE OXIDASE INHIBITORS; PSYCHOTROPIC DRUGS; PYRAZOLES; SULFONAMIDES;

EID: 79959927712     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711795906914     Document Type: Editorial

References (14)

1. Muller, N.; Schwarz, M. J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Muller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N.; Moller, H. J.; Arolt, V.; Riedel, M., The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry, 2006, 11(7), 680-684.
2. Amminger, G. P.; Schafer, M. R.; Papageorgiou, K.; Klier, C. M.; Cotton, S. M.; Harrigan, S. M.; Mackinnon, A.; McGorry, P. D.; Berger, G. E., Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry, 2010, 67(2), 146-154.
3. Horikawa, H.; Kato, T. A.; Mizoguchi, Y.; Monji, A.; Seki, Y.; Ohkuri, T.; Gotoh, L.; Yonaha, M.; Ueda, T.; Hashioka, S.; Kanba, S., Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(7), 1306-1316.
4. Kato, T.; Mizoguchi, Y.; Monji, A.; Horikawa, H.; Suzuki, S. O.; Seki, Y.; Iwaki, T.; Hashioka, S.; Kanba, S., Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J. Neurochem., 2008, 106(2), 815-825.
5. Shoval, G.; Weizman, A., The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol., 2005, 15(3), 319-329.
6. Deltheil, T.; Guiard, B. P.; Cerdan, J.; David, D. J.; Tanaka, K. F.; Reperant, C.; Guilloux, J. P.; Coudore, F.; Hen, R.; Gardier, A. M., Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology, 2008, 55(6), 1006-1014.
7. Hashimoto, K., Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin. Neurosci., 2010, 64(4), 341-357.
8. Bai, O.; Chlan-Fourney, J.; Bowen, R.; Keegan, D.; Li, X. M., Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res., 2003, 71(1), 127-131.
9. Luo, C.; Xu, H.; Li, X. M., Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res., 2004, 1025(1-2), 194-202.
10. Chen, B.; Dowlatshahi, D.; MacQueen, G. M.; Wang, J. F.; Young, L. T., Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry, 2001, 50(4), 260-265.
11. Thompson Ray, M.; Weickert, C. S.; Wyatt, E.; Webster, M. J., Decreased BDNF, trkB-TK+ and GAD(67) mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci., 2011, 36(1), 100048.
12. Makar, T. K.; Bever, C. T.; Singh, I. S.; Royal, W.; Sahu, S. N.; Sura, T. P.; Sultana, S.; Sura, K. T.; Patel, N.; Dhib-Jalbut, S.; Trisler, D., Brainderived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J. Neuroimmunol., 2009, 210(1-2), 40-51.
13. Jiang, Y.; Wei, N.; Lu, T.; Zhu, J.; Xu, G.; Liu, X., Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience, 2011, 172, 398-405.
14. Kreitzer, F. R.; Stella, N., The therapeutic potential of novel cannabinoid receptors. Pharmacol. Ther., 2009, 122(2), 83-96.